DAFTAR PUSTAKA

Allen, R. H., Kaunitz, A. M., & Hickey, M. (2015). Hormonal Contraception. In *Williams Textbook of Endocrinology* (Thirteenth). https://doi.org/10.1016/B978-0-323-29738-7.00018-6

Amanda H. Corbett, W. K. D. (2014). *Drug Information Handbook_23rd.Ed_2014-2015.pdf* (p. 2666).

Anagnostis, P., Selalmatzidou, D., Polyzos, S. A., Panagiotou, A., Slavakis, A., Panagiotidou, A., Athyros, V. G., Karagiannis, A., Mikhailidis, D. P., & Kita, M. (2011). Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: A prospective randomised open-label study. *International Journal of Clinical Practice*, *65*(6), 679–683. https://doi.org/10.1111/j.1742-1241.2011.02655.x

Andersson, H. (2008). Clinical Reproductive Endocrinology. In *Clinical Biochemistry of Domestic Animals (Sixth Edition)* (pp. 635–662). https://doi.org/https://doi.org/10.1016/B978-0-12-370491-7.00021-0

Andrew, G. S. C. (2012). Diagnonis, Classification, Epidemiology and Biochemistry. In *Churchill's Pocketbook of Diabetes (Second Edition)* (pp. 2011–2030). https://doi.org/10.1016/B978-0-443-10081-9.00008-7

Arsana, P. M., Rosandi, R., Manaf, A., Budhiarta, A., & Hikmat Permana. (2019). Pedoman Pengelolaan Dislipidemi di Indonesia 2019. *Pb. Perkeni*, 9. https://doi.org/10.1002/bit.22430

Athyros, V., Kakafika, A., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. (2009). Pleiotropic Effects of Statins - Clinical Evidence. *Current Pharmaceutical Design*, *15*(5), 479–489. https://doi.org/10.2174/138161209787315729

Bellia, A., Rizza, S., Lombardo, M. F., Donadel, G., Fabiano, R., Andreadi, K., Quon, M. J., Sbraccia, P., Federici, M., Tesauro, M., Cardillo, C., & Lauro, D. (2012). Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. *Atherosclerosis*, *223*(1), 197–203. https://doi.org/10.1016/j.atherosclerosis.2012.04.015

Bhattacharya, S., Kundu, R., Dasgupta, S., & Bhattacharya, S. (2012). Mechanism of Lipid Induced Insulin Resistance: An Overview. *Endocrinology and Metabolism*, *27*(1), 12. https://doi.org/10.3803/enm.2012.27.1.12

Brault, M., Ray, J., Gomez, Y., Mantzoros, C. S., & Daskalopoulou, S. S.

(2014). Statin treatment and new-onset diabetes: A review of proposed mechanisms. *Metabolism*, *63*(6), 735–745. https://doi.org/10.1016/j.metabol.2014.02.014

Chahyanto, B. A., Marliyati, S. A. and Winarsih, W. (2017) 'Efek Diet Tinggi Kolesterol Terhadap Peningkatan Kolesterol Darah, Gambaran Histopatologi Hati, dan Bobot Badan Kelinci New Zealand White Jantan', *Jurnal Sain Veteriner*, 34(1), pp. 50–59. doi: 10.22146/jsv.22814.

Damci, T., Tatliagac, S., Osar, Z., & Ilkova, K. (2003). Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. *European Journal of Internal Medicine*, *14*(6), 357–360. https://doi.org/10.1016/S0953-6205(03)90001-X

Del Río, J. P., Alliende, M. I., Molina, N., Serrano, F. G., Molina, S., & Vigil, P. (2018). Steroid Hormones and Their Action in Women's Brains: The Importance of Hormonal Balance. *Frontiers in Public Health*, *6*(May), 1–15. https://doi.org/10.3389/fpubh.2018.00141

Dipiro J, T. Talbert R, L/ Yee, G, C. Matzke, G, R. Wells, B, G. Posey, L, M. (2017). *Pharmacotherapy A Pathophysiologic Approach* (Tenth Edit).

Fargion, S., Dongiovanni, P., Guzzo, A., Colombo, S., Valenti, L., & Fracanzani, A. L. (2005). Iron and insulin resistance. *Alimentary Pharmacology and Therapeutics, Supplement*, *22*(2), 61–63. https://doi.org/10.1111/j.1365-2036.2005.02599.x

Fraulob, J. C., Ogg-Diamantino, R., Fernandes-Santos, C., Aguila, M. B., & Mandarim-de-Lacerda, C. A. (2010). A mouse model of metabolic syndrome: Insulin resistance, fatty liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 mice fed a high fat diet. *Journal of Clinical Biochemistry and Nutrition*, *46*(3), 212–223. https://doi.org/10.3164/jcbn.09-83

Galicia-garcia, U., Jebari, S., Larrea-sebal, A., Uribe, K. B., & Siddiqi, H. (2020). Statin Treatment-Induced Development of Type 2 Diabetes : From Clinical Evidence to Mechanistic Insights. *International Journal of Molecular Sciences*, *21*, 4725. https://doi.org/doi:10.3390/ijms21134725

Green, C. J., & Hodson, L. (2014). The influence of dietary fat on liver fat accumulation. *Nutrients*, *6*(11), 5018–5033. https://doi.org/10.3390/nu6115018

Her, A. Y., Kim, J. Y., Kang, S. M., Choi, D., Jang, Y., Chung, N., Manabe, I., & Lee, S. H. (2010). Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. *Journal of Cardiovascular Pharmacology and*

Therapeutics, *15*(2), 167–174. https://doi.org/10.1177/1074248409357922

Hirschberg, A. L. (2018). Sex hormones , appetite and eating behaviour in women Maturitas Sex hormones , appetite and eating behaviour in women. *Maturitas*, *71*(3), 248–256. https://doi.org/10.1016/j.maturitas.2011.12.016

Hyun, M. H., Jang, J. W., Choi, B. G., Na, J. O., Choi, C. U., Kim, J. W., Kim, E. J., Rha, S. W., Park, C. G., Lee, E., & Seo, H. S. (2020). Risk of insulin resistance with statin therapy in individuals without dyslipidemia: A propensity-matched analysis in a registry population. *Clinical and Experimental Pharmacology and Physiology*, *47*(6), 947–954. https://doi.org/10.1111/1440-1681.13272

Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, *444*(7121), 840–846. https://doi.org/10.1038/nature05482

Keating, G. M. (2011). Fenofibrate: A review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. *American Journal of Cardiovascular Drugs*, *11*(4), 227–247. https://doi.org/10.2165/11207690-000000000-00000

Kementrian Kesehatan Republik Indonesia. (2014). *Situasi dan Analisis Keluarga Berencana di Indonesia*. Pusat Data dan Informasi Kementrian Kesehatan Republik Indonesia.

Kim, J., Lee, H. S., & Lee, K. Y. (2018). Effect of statins on fasting glucose in non - diabetic individuals : nationwide population - based health examination in Korea. *Cardiovascular Diabetology*, 1–11. https://doi.org/10.1186/s12933-018-0799-4

Koh, Kwang Kon. Quon Michael J. Han, Seung Hwan. Lee Yonghee. Ahn Jeong Yeal. Kim Soo Jin. Koh Yesl. Shin, E. K. (2008). Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients. *Diabetes Care*, *31*. https://doi.org/10.2337/dc07-2199.Clinical

Krysiak, R., & Okopien, B. (2013). Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. *Pharmacology*, *92*(3–4), 187–190. https://doi.org/10.1159/000341909

Lebovitz, H. E. (2016). chapter 42 - Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. In *Endocrinology: Adult and Pediatric, 2-Volume Set* (Seventh Ed). https://doi.org/10.1016/B978-0-323-18907-1.00042-1

Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012). Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular

disease. *Clinical Medicine Insights: Cardiology*, *6*, 17–33. https://doi.org/10.4137/CMC.S4324

Meisenberg, G., & Simmons, W. H. (2012). Integration of Metabolism. In *Principles of Medical Biochemistry* (Issue October 2019). https://doi.org/10.1016/b978-0-323-07155-0.00030-7

Moreno-Fernández, S., Garcés-Rimón, M., Vera, G., Astier, J., Landrier, J. F., & Miguel, M. (2018). High fat/high glucose diet induces metabolic syndrome in an experimental rat model. *Nutrients*, *10*(10), 1–15. https://doi.org/10.3390/nu10101502

Nair, A., & Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. *Journal of Basic and Clinical Pharmacy*, *7*(2), 27. https://doi.org/10.4103/0976-0105.177703

Nolan, C. J., & Prentki, M. (2019). Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. *Diabetes and Vascular Disease Research*, *16*(2), 118–127. https://doi.org/10.1177/1479164119827611

Olatunji, L. A., Michael, O. S., Adewumi, F. O., Aiyegboyin, I. J., & Olatunji, V. A. (2012). Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. *Pathophysiology*, *19*(1), 29–34. https://doi.org/10.1016/j.pathophys.2011.09.001

Pallardo, L. F., Cano, A., Cristobal, I., Blanco, M. A., Lozano, M., & Lete, I. (2012). Hormonal Contraception and Diabetes. *Clinical Medicine Insights: Women's Health*, *5*, CMWH.S9934. https://doi.org/10.4137/cmwh.s9934

Paseban, M., Butler, A. E., & Sahebkar, A. (2019). Mechanisms of statin-induced new-onset diabetes. *Journal of Cellular Physiology*, *234*(8), 12551–12561. https://doi.org/10.1002/jcp.28123

Qu, H. Q., Li, Q., Rentfro, A. R., Fisher-Hoch, S. P., & McCormick, J. B. (2011). The definition of insulin resistance using HOMA-IR for americans of mexican descent using machine learning. *PLoS ONE*, *6*(6), 4–7. https://doi.org/10.1371/journal.pone.0021041

Ramakrishnan, S. K., Russo, L., Ghanem, S. S., Patel, P. R., Oyarce, A. M., Heinrich, G., & Najjar, S. M. (2016). Fenofibrate decreases insulin clearance and insulin secretion to maintain insulin sensitivity. *Journal of Biological Chemistry*, *291*(46), 23915–23924. https://doi.org/10.1074/jbc.M116.745778

Salunkhe, V. A., Mollet, I. G., Ofori, J. K., Malm, H. A., Esguerra, J. L. S., Reinbothe, T. M., Stenkula, K. G., Wendt, A., Eliasson, L., & Vikman,

J. (2016). Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion. *EBioMedicine*, *10*, 185–194. https://doi.org/10.1016/j.ebiom.2016.07.007

Scattolini, V., Luni, C., Zambon, A., Galvanin, S., Gagliano, O., Ciubotaru, C. D., Avogaro, A., Mammano, F., Elvassore, N., & Fadini, G. P. (2016). Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. *Diabetes Therapy*, *7*(4), 679–693. https://doi.org/10.1007/s13300-016-0210-y

Shinta A.P, K. M. . (2014). Online di : http://ejournal-s1.undip.ac.id/index.php/jnc. *Journal of Nutrition College*, *3*(1), 90–97.

Soska, V., Fiala, J., Nebeska, K., Jarkovsky, J., & Hruba, D. (2011). The atherogenic index of plasma is increased by hormonal contraception. *Scandinavian Journal of Clinical and Laboratory Investigation*, *71*(2), 94–100. https://doi.org/10.3109/00365513.2011.553240

Szendroedi, J., Anderwald, C., Krssak, M., Bayerle-Eder, M., Esterbauer, H., Pfeiler, G., Brehm, A., Nowotny, P., Hofer, A., Waldhausl, W., & Roden, M. (2009). Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. *Diabetes Care*, *32*(2), 209–214. https://doi.org/10.2337/dc08-1123

Williams, D., & Feely, J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. *Clinical Pharmacokinetics*, *41*(5), 343–370. https://doi.org/10.2165/00003088-200241050-00003

Lampiran

Lampiran 1. Alur Penelitian



Lampiran 2. Dokumentasi penelitian

Gambar 11. Masa aklimatisasi hewan uji di laboratorium

Gambar 12. Proses pemberian peroral

Gambar 13. Proses penimbangan bahan

Gambar 14. Proses pembiusan hewan uji

Lampiran 3. Perhitungan dosis

1. Perhitungan tablet pil kontrasepsi

Tabel 5. Berat 20 tablet pil kontrasepsi (gram)

0.0764	0.0758
0.0731	0.0763
0.0751	0.0770
0.0794	0.0762
0.0735	0.0758
0.0730	0.0769
0.0765	0.0708
0.0785	0.0776
0.0726	0.0809
0.0806	0.0727
Berat rata-rata 0.075935 gram = 75,935 mg	

Satu tablet pil kontrasepsi mengandung 0.15mg levonorgestrel setara dengan 2.5µg/kgBB dan 0.03mg ethinylestradiol setara dengan 0.5µg/kgBB.

Maka dosis untuk tikus

Levonorgestrel

= 2.5µg/kgBB x 6.2 = 15.5µg/kgBB

Ethinylestradiol

= 0.5µg/kgBB x 6.2 = 3.1µg/kgBB

Dosis yang diinginkan untuk bobot badan tikus 200gram

Levonorgestrel

$$\frac{15.5\ \mu g/kgBB}{1000\ gram} = \frac{X}{200\ gram}$$

X = 3.1µg/gBB

Ethinylestradiol

$\frac{3.1\ \mu g/kgBB}{1000\ gram} = \frac{X}{200\ gram}$

X = 0.62µg/gBB

Berat yang ditimbang

Levonorgestrel

$= \frac{3.1\ \mu g}{0.15\ mg}$ x 75.93 mg = 1569.32µg

Ethinylestradiol

$= \frac{0.62\ \mu g}{0.03\ mg}$ x 75.93 mg

= 1569.32 µg

Untuk tikus dengan bobot badan 200gram dosis Pil kontrasepsi

= 1569.32µg + 1569.32µg

= 3138.64µg

= 3.13684mg

= 3.14mg

Untuk stock 100ml dengan bobot badan tikus 200gram

$= \frac{3.14\ mg}{2\ ml}$ x 100ml

= 157mg

= 0.15gram

2. Perhitungan tablet simvastatin 20 mg

Tabel 6. Berat 20 tablet simvastatin 20 mg (gram)

0.2043	0.1981
0.2042	0.2015
0.2049	0.2012
0.2054	0.2104
0.2066	0.2012

0.1951	0.2000
0.2065	0.2040
0.2058	0.2039
0.2020	0.2119
0.2022	0.2022
Berat rata-rata 0,20357 gram = 203,57 mg	

Untuk simvastatin 20 mg

20 mg / 60 kgbb setara dengan 0.33 mg/kgbb maka dosis untuk tikus dengan bobot badan 200 g

= dosis x 6.2

= 0.33 mg / kgbb x 6.2 = 2.1 mg/kgbb

= 2.1 mg / 1000gbb

= 0.42 mg / 200gbb

Berat simvastatin 20mg

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{0.42\ mg}{20\ mg}$ x 203.57 mg

= 4.27497 mg

= 4.3 mg

Untuk larutan stock untuk 25 ml pada tikus 200 g

= $\frac{4.3\ mg}{2ml}$ x 25 ml

= 53.75 mg

= 0.05375 g

= 0.05 g

Konsentrasi simvastatin 20 mg sebanyak 53,75 mg yang dilarutkan dalam 25 ml NaCMC 0,5%

53,75 x 4 = 25 x 4

215 mg = 100 ml

0,215 g = 100 ml

= 0,21 % (b/v)

3. Perhitungan kapsul fenofibrate 100 mg.

Tabel 7**.** Berat 20 kapsul fenofibrate 100 mg (gram)

0.2886	0.2350
0.2377	0.2406
0.2464	0.2484
0.2418	0.2240
0.2426	0.2537
0.2416	0.2481
0.2443	0.1922
0.2442	0.2468
0.2500	0.2330
0.2330	0.2416
Berat rata-rata 0.24168 gram = 241.68 mg	

Untuk fenofibrate 100 mg

80 mg / 60 kgbb setara dengan 1.33 mg/kgbb maka dosis untuk tikus dengan 200 g

= dosis x 6.2

= 1.33mg/kgbb x 6.2

= 8.24 mg/kgbb

= 8.24 mg / 1000 gbb

= 1.65 mg / 200 gbb

Berat fenofibrate 100 mg

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{1.6492mg}{100mg}$ x 241.68 mg

= 3.9 mg

Untuk larutan stock untuk 25 ml pada tikus 200 gram

= $\frac{3.9857\ mg}{2\ ml}$ x 25 ml

= 49.82 mg

= 0,05 gram

Konsentrasi fenofibrat 100 mg sebanyak 49,82 mg yang dilarutkan dalam 25 ml NaCMC 0,5%

49,82 x 4 = 25 x 4

199,28 mg = 100 ml

0,19 g = 100 ml

= 0,19 %(b/v)

4. Perhitungan tablet rosuvastatin 10 mg

Tabel 8. Berat 20 tablet Rosuvastatin 10 mg (gram)

0.0822	0.0828
0.0849	0.0846
0.0842	0.0885
0.0832	0.0857
0.0853	0.0837
0.0849	0.0881
0.0867	0.0854
0.0856	0.0857
0.0863	0.0858
0.0868	0.0839
Berat rata-rata 0.085215 gram = 85.21 mg	

Untuk Rosuvastatin 10 mg

5 mg/60kgbb setara dengan 0.083 mg/kgbb maka dosis untuk tikus dengan 200 g

= dosis x 6.2

= 0.083 mg/kgbb x 6.2

= 0.51 mg/kgbb

= 0.51 mg/1000gbb

= 0.10 mg/200gbb

Berat rosuvastatin 10 mg yang ditimbang

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{0.10292\ mg}{10mg}$ x 85.21 mg

= 0.87 mg

Untuk larutan stok untuk 25 ml pada tikus 200 g

= $\frac{0.87703\ mg}{2\ ml}$ x 25 ml

= 10.96mg

= 0.01gram

Konsentrasi rosuvastatin 10 mg sebanyak 10,96 mg yang dilarutkan dalam 25 ml NaCMC 0,5%

10,96 x 4 = 25 x 4

43,84 mg = 100 ml

0,04 g = 100 ml

= 0,04 %(b/v)

Lampiran 4. Data statistik

1. Uji Normalitas

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
gdp0	.146	18	.200*	.964	18	.674
gdp30	.107	18	.200*	.971	18	.807
gdp60	.157	18	.200*	.934	18	.228
insulin0	.091	18	.200*	.960	18	.604
insulin30	.125	18	.200*	.958	18	.561
insulin60	.124	18	.200*	.951	18	.442
homa0	.096	18	.200*	.979	18	.939
homa30	.103	18	.200*	.964	18	.687
homa60	.155	18	.200*	.951	18	.440

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

2. Uji T Berpasangan

a. Perlakuan Pil KB

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	a_gdp0	56.8767	3	15.13424	8.73776
	a_gdp30	75.7567	3	10.59200	6.11530
Pair 2	a_gdp30	75.7567	3	10.59200	6.11530
	a_gdp60	76.0667	3	4.81437	2.77958
Pair 3	a_insulin0	3.7211	3	1.57505	.90936
	a_insulin30	3.7839	3	.63767	.36816
Pair 4	a_insulin30	3.7839	3	.63767	.36816
	a_insulin60	4.3560	3	.54122	.31247
Pair 5	a_homa0	.5300	3	.24576	.14189
	a_homa30	.7133	3	.19757	.11407
Pair 6	a_homa30	.7133	3	.19757	.11407
	a_homa60	.8133	3	.05686	.03283

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	a_gdp0 & a_gdp30	3	.059	.962
Pair 2	a_gdp30 & a_gdp60	3	.808	.401
Pair 3	a_insulin0 & a_insulin30	3	.740	.470
Pair 4	a_insulin30 & a_insulin60	3	-.978	.134
Pair 5	a_homa0 & a_homa30	3	.980	.126
Pair 6	a_homa30 & a_homa60	3	-.415	.727

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	a_gdp0 - a_gdp30	-18.88000	17.95420	10.36586	-63.48071	25.72071	-1.821	2	.210
Pair 2	a_gdp30 - a_gdp60	-.31000	7.27486	4.20014	-18.38176	17.76176	-.074	2	.948
Pair 3	a_insulin0 - a_insulin30	-.06277	1.18352	.68331	-3.00280	2.87727	-.092	2	.935
Pair 4	a_insulin30 - a_insulin60	-.57213	1.17236	.67686	-3.48443	2.34016	-.845	2	.487
Pair 5	a_homa0 - a_homa30	-.18333	.06506	.03756	-.34496	-.02171	-4.880	2	.040
Pair 6	a_homa30 - a_homa60	-.10000	.22716	.13115	-.66429	.46429	-.762	2	.525

b. Perlakuan pakan lemak

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	b_gdp0	53.7100	3	13.35415	7.71002
	b_gdp30	78.9733	3	19.50665	11.26217
Pair 2	b_gdp30	78.9733	3	19.50665	11.26217
	b_gdp60	93.5533	3	13.02302	7.51884
Pair 3	b_insulin0	6.2002	3	.81830	.47245
	b_insulin30	3.8013	3	.57425	.33154
Pair 4	b_insulin30	3.8013	3	.57425	.33154
	b_insulin60	3.7267	3	.69245	.39979
Pair 5	b_homa0	.8133	3	.18037	.10414
	b_homa30	.7567	3	.27683	.15983
Pair 6	b_homa30	.7567	3	.27683	.15983
	b_homa60	.8733	3	.25658	.14814

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	b_gdp0 & b_gdp30	3	-.256	.835
Pair 2	b_gdp30 & b_gdp60	3	.920	.256
Pair 3	b_insulin0 & b_insulin30	3	-1.000	.012
Pair 4	b_insulin30 & b_insulin60	3	.420	.724
Pair 5	b_homa0 & b_homa30	3	-.455	.699
Pair 6	b_homa30 & b_homa60	3	.942	.218

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	b_gdp0 - b_gdp30	-25.26333	26.31067	15.19047	-90.62266	40.09599	-1.663	2	.238
Pair 2	b_gdp30 - b_gdp60	-14.58000	9.08005	5.24237	-37.13609	7.97609	-2.781	2	.109
Pair 3	b_insulin0 - b_insulin30	2.39890	1.39249	.80395	-1.06023	5.85803	2.984	2	.096
Pair 4	b_insulin30 - b_insulin60	.07463	.68912	.39786	-1.63723	1.78649	.188	2	.869
Pair 5	b_homa0 - b_homa30	.05667	.39323	.22703	-.92018	1.03352	.250	2	.826
Pair 6	b_homa30 - b_homa60	-.11667	.09292	.05364	-.34748	.11415	-2.175	2	.162

c. Perlakuan pil KB+pakan lemak

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	c_gdp0	71.1133	3	4.83388	2.79084
	c_gdp30	52.1533	3	26.13051	15.08645
Pair 2	c_gdp30	52.1533	3	26.13051	15.08645
	c_gdp60	75.0233	3	7.15188	4.12914
Pair 3	c_insulin0	3.7675	3	.67986	.39252
	c_insulin30	4.4389	3	.38257	.22088
Pair 4	c_insulin30	4.4389	3	.38257	.22088
	c_insulin60	3.6650	3	.72045	.41595
Pair 5	c_homa0	.6667	3	.15044	.08686
	c_homa30	.5667	3	.27135	.15667
Pair 6	c_homa30	.5667	3	.27135	.15667
	c_homa60	.6833	3	.18771	.10837

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	c_gdp0 & c_gdp30	3	.997	.047
Pair 2	c_gdp30 & c_gdp60	3	.969	.160
Pair 3	c_insulin0 & c_insulin30	3	.609	.583
Pair 4	c_insulin30 & c_insulin60	3	-.904	.281
Pair 5	c_homa0 & c_homa30	3	.825	.382
Pair 6	c_homa30 & c_homa60	3	.769	.442

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	c_gdp0 - c_gdp30	18.96000	21.31310	12.30512	-33.98467	71.90467	1.541	2	.263
Pair 2	c_gdp30 - c_gdp60	-22.87000	19.28370	11.13345	-70.77337	25.03337	-2.054	2	.176
Pair 3	c_insulin0 - c_insulin30	-.67143	.54012	.31184	-2.01317	.67030	-2.153	2	.164
Pair 4	c_insulin30 - c_insulin60	.77387	1.07876	.62283	-1.90593	3.45367	1.243	2	.340
Pair 5	c_homa0 - c_homa30	.10000	.17000	.09815	-.32230	.52230	1.019	2	.415
Pair 6	c_homa30 - c_homa60	-.11667	.17474	.10088	-.55074	.31741	-1.156	2	.367

d. Perlakuan pil KB+pakan lemak+simvastatin

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	d_gdp0	64.9400	3	.26058	.15044
	d_gdp30	77.5700	3	8.76002	5.05760
Pair 2	d_gdp30	77.5700	3	8.76002	5.05760
	d_gdp60	55.7200	3	1.97477	1.14013
Pair 3	d_insulin0	4.8579	3	2.02760	1.17064
	d_insulin30	4.3315	3	.92649	.53491
Pair 4	d_insulin30	4.3315	3	.92649	.53491
	d_insulin60	4.2065	3	.39303	.22692
Pair 5	d_homa0	.7767	3	.32624	.18836
	d_homa30	.8233	3	.14048	.08110
Pair 6	d_homa30	.8233	3	.14048	.08110
	d_homa60	.5800	3	.06083	.03512

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	d_gdp0 & d_gdp30	3	-.012	.993
Pair 2	d_gdp30 & d_gdp60	3	.998	.045
Pair 3	d_insulin0 & d_insulin30	3	.455	.699
Pair 4	d_insulin30 & d_insulin60	3	.660	.541
Pair 5	d_homa0 & d_homa30	3	.831	.376
Pair 6	d_homa30 & d_homa60	3	.772	.438

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	d_gdp0 - d_gdp30	-12.63000	8.76694	5.06159	-34.40828	9.14828	-2.495	2	.130
Pair 2	d_gdp30 - d_gdp60	21.85000	6.79149	3.92107	4.97899	38.72101	5.572	2	.031
Pair 3	d_insulin0 - d_insulin30	.52643	1.80559	1.04246	-3.95891	5.01177	.505	2	.664
Pair 4	d_insulin30 - d_insulin60	.12493	.72967	.42128	-1.68768	1.93754	.297	2	.795
Pair 5	d_homa0 - d_homa30	-.04667	.22368	.12914	-.60232	.50899	-.361	2	.752
Pair 6	d_homa30 - d_homa60	.24333	.10116	.05840	-.00796	.49463	4.166	2	.053

e. Perlakuan pil KB+pakan lemak+rosuvastatin

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	e_gdp0	54.6133	3	5.56088	3.21058
	e_gdp30	99.8233	3	8.51127	4.91398
Pair 2	e_gdp30	99.8233	3	8.51127	4.91398
	e_gdp60	54.8233	3	3.75455	2.16769
Pair 3	e_insulin0	3.7720	3	1.21526	.70163
	e_insulin30	4.4081	3	1.14402	.66050
Pair 4	e_insulin30	4.4081	3	1.14402	.66050
	e_insulin60	3.4983	3	.64788	.37406
Pair 5	e_homa0	.5200	3	.21517	.12423
	e_homa30	1.0967	3	.32316	.18658
Pair 6	e_homa30	1.0967	3	.32316	.18658
	e_homa60	.4767	3	.10970	.06333

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	e_gdp0 & e_gdp30	3	-1.000	.020
Pair 2	e_gdp30 & e_gdp60	3	.627	.569
Pair 3	e_insulin0 & e_insulin30	3	-.540	.637
Pair 4	e_insulin30 & e_insulin60	3	-.918	.259
Pair 5	e_homa0 & e_homa30	3	-.731	.478
Pair 6	e_homa30 & e_homa60	3	-.652	.548

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	e_gdp0 - e_gdp30	-45.21000	14.07053	8.12362	-80.16312	-10.25688	-5.565	2	.031
Pair 2	e_gdp30 - e_gdp60	45.00000	6.81859	3.93672	28.06168	61.93832	11.431	2	.008
Pair 3	e_insulin0 - e_insulin30	-.63613	2.07027	1.19527	-5.77896	4.50670	-.532	2	.648
Pair 4	e_insulin30 - e_insulin60	.90983	1.75777	1.01485	-3.45672	5.27639	.897	2	.465
Pair 5	e_homa0 - e_homa30	-.57667	.50243	.29008	-1.82477	.67143	-1.988	2	.185
Pair 6	e_homa30 - e_homa60	.62000	.40336	.23288	-.38200	1.62200	2.662	2	.117

f. Perlakuan pil KB+pakan lemak+fenofibrat

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	f_gdp0	80.8633	3	20.74098	11.97481
	f_gdp30	97.9100	3	24.98740	14.42648
Pair 2	f_gdp30	97.9100	3	24.98740	14.42648
	f_gdp60	52.7533	3	9.26472	5.34899
Pair 3	f_insulin0	4.4204	3	.38790	.22395
	f_insulin30	4.0190	3	.10537	.06084
Pair 4	f_insulin30	4.0190	3	.10537	.06084
	f_insulin60	3.3316	3	.28930	.16703
Pair 5	f_homa0	.8833	3	.25541	.14746
	f_homa30	.9733	3	.23861	.13776
Pair 6	f_homa30	.9733	3	.23861	.13776
	f_homa60	.4300	3	.03606	.02082

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	f_gdp0 & f_gdp30	3	.931	.239
Pair 2	f_gdp30 & f_gdp60	3	.258	.834
Pair 3	f_insulin0 & f_insulin30	3	.987	.103
Pair 4	f_insulin30 & f_insulin60	3	-.965	.169
Pair 5	f_homa0 & f_homa30	3	.829	.378
Pair 6	f_homa30 & f_homa60	3	.628	.568

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	f_gdp0 - f_gdp30	-17.04667	9.48478	5.47604	-40.60816	6.51483	-3.113	2	.090
Pair 2	f_gdp30 - f_gdp60	45.15667	24.30186	14.03069	-15.21250	105.52584	3.218	2	.084
Pair 3	f_insulin0 - f_insulin30	.40140	.28440	.16420	-.30508	1.10788	2.445	2	.134
Pair 4	f_insulin30 - f_insulin60	.68737	.39196	.22630	-.28631	1.66105	3.037	2	.093
Pair 5	f_homa0 - f_homa30	-.09000	.14526	.08386	-.45084	.27084	-1.073	2	.396
Pair 6	f_homa30 - f_homa60	.54333	.21779	.12574	.00231	1.08436	4.321	2	.050

3. Uji Anova

a. Data GDP

Tests of Between-Subjects Effects

Dependent Variable: gdp60

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	4162.628[a]	7	594.661	11.760	.000
Intercept	83207.522	1	83207.522	1645.553	.000
perlakuan	3972.763	5	794.553	15.713	.000
kelompok	189.865	2	94.933	1.877	.203
Error	505.651	10	50.565		
Total	87875.801	18			
Corrected Total	4668.279	17			

a. R Squared = .892 (Adjusted R Squared = .816)

gdp60

Tukey HSD[a,b]

perlakuan	N	Subset 1	Subset 2	Subset 3
6.00	3	52.7533		
5.00	3	54.8233		
4.00	3	55.7200	55.7200	
3.00	3		75.0233	75.0233
1.00	3			76.0667
2.00	3			93.5533
Sig.		.994	.063	.077

Means for groups in homogeneous subsets are displayed.

Based on observed means.

The error term is Mean Square(Error) = 50.565.

a. Uses Harmonic Mean Sample Size = 3.000.

b. Alpha = 0,05.

b. Data Insulin

Tests of Between-Subjects Effects

Dependent Variable: insulin60

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	3.069[a]	7	.438	1.347	.323
Intercept	259.559	1	259.559	797.365	.000
perlakuan	2.425	5	.485	1.490	.276
kelompok	.644	2	.322	.988	.406
Error	3.255	10	.326		
Total	265.883	18			
Corrected Total	6.324	17			

a. R Squared = .485 (Adjusted R Squared = .125)

c. Data Homa (IR)

Tests of Between-Subjects Effects

Dependent Variable: homa60

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	.542[a]	7	.077	4.248	.020
Intercept	7.437	1	7.437	407.752	.000
perlakuan	.482	5	.096	5.286	.012
kelompok	.060	2	.030	1.652	.240
Error	.182	10	.018		
Total	8.162	18			
Corrected Total	.725	17			

a. R Squared = .748 (Adjusted R Squared = .572)

homa60

Tukey HSD[a,b]

perlakuan	N	Subset 1	Subset 2	Subset 3
6.00	3	.4300		
5.00	3	.4767	.4767	
4.00	3	.5800	.5800	.5800
3.00	3	.6833	.6833	.6833
1.00	3		.8133	.8133
2.00	3			.8733
Sig.		.278	.094	.168

Means for groups in homogeneous subsets are displayed.

Based on observed means.

The error term is Mean Square(Error) = .018.

a. Uses Harmonic Mean Sample Size = 3.000.

b. Alpha = 0,05.

Lampiran 5. Rekomendasi persetujuan etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 334/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 20 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21030163	No Sponsor Protokol	
Peneliti Utama	**Sitti Hadijah, S.Farm., Apt.**	Sponsor	
Judul Peneliti	Evaluasi Risiko Penurunan Sensitivitas Insulin Akibat Simvastatin dan Rosuvastatin pada Tikus Betina Dislipidemia yang Diinduksi Kontrasepsi Oral		
No Versi Protokol	**2**	Tanggal Versi	**26 April 2021**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	**Fakultas Farmasi Universitas Hasanuddin Makassar**		
Jenis Review	[ ] Exempted [x] Expedited [ ] Fullboard Tanggal	Masa Berlaku **20 Mei 2021** sampai **20 Mei 2022**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan